Glp-1 agonists and insulin resistance: effects of liraglutide on adipose tissue remodeling.

MORALES, CELINA; BERMEJO, M; FRIEDMAN, SILVIA; BERG, GABRIELA; FINOCCHIETO, P; LOPEZ, GRACIELA; BARCHUK, MAGALÍ; SCHREIER, LAURA; TOUCEDA, V; CEVEY, ÀGATA CAROLINA; QUINTANILLA, M; GOREN, NORA BEATRIZ; MIKSZTOWICZ, VERÓNICA

Mar del Plata

Congreso; LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica. 1; 2019

Sociedad Argentina de Investigación Clínica

Insulin-resistance (IR) is characterized by adipose tissue (AT) expansion associated with hypoxia and dysfunction. Liraglutide, a glucagon-like peptide type 1 (GLP-1) agonist, has emerged for the management of IR, however it is unknown the direct effects on expanded AT. Aim: to evaluate the role of liraglutide on AT remodeling in an animal model of IR. Methods: male Wistar rats (180-200 g) were divided into 2 groups: Control (C, n=8) fed with standard diet, and sucrose rich diet group (SRD, n=8) fed with standard diet and sucrose 30% in drinking water during 15 weeks. Then, both groups were subdivided according to the subcutaneous administration of liraglutide (L, 0.6 mg/kg/day) for 5 weeks. The study was approved by the Ethic Committee-FFYB (UBA). Serum glucose, total cholesterol (t-chol) and triglycerides (TG) were measured pre and post- L administration. Visceral AT (perirrenal, intestinal and epididymal) was removed and weighed. In epididymal AT (EAT) histological characteristics (adipocyte area and adipocyte and vascular density), mitochondrial density by electronic transmission microscopy and uncoupling protein-1 (UCP-1) and hypoxia-inducible factor alpha 1 (HIF-1α) RNAm levels were evaluated. Results: as expected, SRD presented higher visceral AT mass (p